Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Invested Capital (2016 - 2025)

Sangamo Therapeutics (SGMO) has 9 years of Return on Invested Capital data on record, last reported at 8.4% in Q3 2025.

  • For Q3 2025, Return on Invested Capital fell 395.0% year-over-year to 8.4%; the TTM value through Sep 2025 reached 8.4%, down 395.0%, while the annual FY2024 figure was 1.96%, 54.0% down from the prior year.
  • Return on Invested Capital reached 8.4% in Q3 2025 per SGMO's latest filing, down from 5.11% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.27% in Q1 2021 and bottomed at 8.4% in Q3 2025.
  • Average Return on Invested Capital over 5 years is 2.5%, with a median of 0.74% recorded in 2023.
  • Peak YoY movement for Return on Invested Capital: tumbled -569bps in 2024, then surged 131bps in 2025.
  • A 5-year view of Return on Invested Capital shows it stood at 0.47% in 2021, then plummeted by -42bps to 0.67% in 2022, then tumbled by -269bps to 2.47% in 2023, then plummeted by -36bps to 3.35% in 2024, then plummeted by -151bps to 8.4% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 8.4% in Q3 2025, 5.11% in Q2 2025, and 5.92% in Q1 2025.